Source Citation

Levi M, Levy M, Williams MD, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007;176:483-90.

Clinical Impact Ratings

Hospitalists: 6 out of 7

Hematology: 7 out of 7

Infectious Disease: 6 out of 7

Critical Care: 6 out of 7


  • 1 Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709. [PMID: 11236773] Google Scholar
  • 2 FDA briefing document: anti-infective advisory committee drotrecogin alfa (activated). (accessed on 20 December 2007). Google Scholar
  • 3 Zarychanski R, Gulati H, Roberts D, et al. Systemically administered therapeutic dose heparin is associated with increased survival in patients diagnosed with septic shock. Crit Care Med. 2006;34 (suppl):A110, 398. Google Scholar
  • 4 Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338S-400S. [PMID: 15383478] Google Scholar